MX2016008639A - Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos. - Google Patents

Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos.

Info

Publication number
MX2016008639A
MX2016008639A MX2016008639A MX2016008639A MX2016008639A MX 2016008639 A MX2016008639 A MX 2016008639A MX 2016008639 A MX2016008639 A MX 2016008639A MX 2016008639 A MX2016008639 A MX 2016008639A MX 2016008639 A MX2016008639 A MX 2016008639A
Authority
MX
Mexico
Prior art keywords
rsv
specific antibodies
functional parts
producing
methods
Prior art date
Application number
MX2016008639A
Other languages
English (en)
Inventor
Kallewaard-Lelay Nicole
Ulbrandt Nancy
Q Yuan Andy
Richter Bettina
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2016008639A publication Critical patent/MX2016008639A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud proporciona anticuerpos y equivalentes funcionales de los mismos que tienen la capacidad de unirse específicamente al VRS, así como medios y métodos para producirlos.
MX2016008639A 2014-01-15 2015-01-14 Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos. MX2016008639A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461927819P 2014-01-15 2014-01-15
PCT/US2015/011391 WO2015108967A2 (en) 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof

Publications (1)

Publication Number Publication Date
MX2016008639A true MX2016008639A (es) 2017-02-15

Family

ID=53543612

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008639A MX2016008639A (es) 2014-01-15 2015-01-14 Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos.

Country Status (24)

Country Link
US (5) US20160340414A1 (es)
EP (3) EP3741390A1 (es)
JP (3) JP6836398B2 (es)
KR (1) KR102188437B1 (es)
CN (2) CN116355080A (es)
AU (3) AU2015206570A1 (es)
CA (1) CA2933200A1 (es)
CY (1) CY1123425T1 (es)
DK (1) DK3094353T3 (es)
ES (1) ES2795727T3 (es)
FI (1) FIC20230016I1 (es)
FR (1) FR23C1016I1 (es)
HK (1) HK1225992A1 (es)
HR (1) HRP20200607T1 (es)
HU (2) HUE048855T2 (es)
LT (2) LT3094353T (es)
MX (1) MX2016008639A (es)
NL (1) NL301228I2 (es)
PL (1) PL3094353T3 (es)
PT (1) PT3094353T (es)
RS (1) RS60387B1 (es)
SI (1) SI3094353T1 (es)
TW (1) TWI705974B (es)
WO (1) WO2015108967A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP3741390A1 (en) 2014-01-15 2020-11-25 Medlmmune, LLC Rsv-specific antibodies and functional parts thereof
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
CN111936513A (zh) * 2018-01-31 2020-11-13 威斯塔解剖学和生物学研究所 用于抗呼吸道合胞病毒的核酸抗体构筑体
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
AU2022341188A1 (en) 2021-09-13 2024-03-14 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
CN116987183A (zh) * 2022-07-22 2023-11-03 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
WO2006050166A2 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
US7632497B2 (en) * 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
HUE033630T2 (en) * 2006-10-02 2017-12-28 Squibb & Sons Llc CXCR4 binding human antibodies and their use
JP2010534057A (ja) 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ 呼吸器合胞体ウイルス感染症を治療するための組換え抗体
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
KR20100049568A (ko) * 2007-06-26 2010-05-12 메디뮨 엘엘씨 Ｒｓｖ 감염 및 관련 병증의 치료 방법
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2454283B1 (en) * 2009-07-15 2018-03-14 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
KR101789343B1 (ko) * 2009-10-06 2017-10-23 메드임뮨 리미티드 Ｒｓｖ-특이적 결합 분자
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US20120263715A1 (en) 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
AU2013234046B2 (en) * 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
EP2852411A4 (en) * 2012-05-22 2016-01-13 Shire Human Genetic Therapies ANTI-CCL2 ANTIBODIES FOR THE TREATMENT OF SCLEROMERMIA
PL2950886T3 (pl) 2013-02-01 2020-06-01 Medimmune, Llc Epitopy białka F syncytialnego wirusa oddechowego
EP3741390A1 (en) 2014-01-15 2020-11-25 Medlmmune, LLC Rsv-specific antibodies and functional parts thereof
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2018158332A1 (en) 2017-03-01 2018-09-07 Medimmune Limited Formulations of monoclonal antibodies

Also Published As

Publication number Publication date
WO2015108967A3 (en) 2015-09-03
BR112016015044A8 (pt) 2023-04-11
RU2016133247A3 (es) 2019-01-16
TW201612191A (en) 2016-04-01
BR112016015044A2 (pt) 2017-09-19
JP6836398B2 (ja) 2021-03-03
EP3094353B1 (en) 2020-04-01
JP2023052693A (ja) 2023-04-11
ES2795727T3 (es) 2020-11-24
FIC20230016I1 (fi) 2023-04-26
EP3094353A4 (en) 2017-09-06
KR20160104018A (ko) 2016-09-02
SI3094353T1 (sl) 2020-07-31
AU2015206570A1 (en) 2016-07-14
RS60387B1 (sr) 2020-07-31
TWI705974B (zh) 2020-10-01
US11661449B2 (en) 2023-05-30
US20230365660A1 (en) 2023-11-16
EP3094353A2 (en) 2016-11-23
US20160340414A1 (en) 2016-11-24
HRP20200607T1 (hr) 2020-07-10
EP3741390A1 (en) 2020-11-25
WO2015108967A2 (en) 2015-07-23
JP2017504321A (ja) 2017-02-09
LTPA2023514I1 (es) 2023-05-25
US10689437B2 (en) 2020-06-23
US20200331989A1 (en) 2020-10-22
CY1123425T1 (el) 2021-12-31
FR23C1016I1 (fr) 2023-06-23
KR102188437B1 (ko) 2020-12-08
PL3094353T3 (pl) 2020-09-07
US11186628B2 (en) 2021-11-30
NL301228I2 (nl) 2023-09-13
CA2933200A1 (en) 2015-07-23
NL301228I1 (es) 2023-05-03
PT3094353T (pt) 2020-06-08
HK1225992A1 (zh) 2017-09-22
JP2020103293A (ja) 2020-07-09
EP4353316A2 (en) 2024-04-17
DK3094353T3 (da) 2020-06-02
AU2021204339A1 (en) 2021-07-22
HUE048855T2 (hu) 2020-08-28
CN105916520A (zh) 2016-08-31
HUS2300019I1 (hu) 2023-05-28
CN116355080A (zh) 2023-06-30
WO2015108967A8 (en) 2015-10-01
AU2020203831A1 (en) 2020-07-02
LT3094353T (lt) 2020-08-10
US20190106482A1 (en) 2019-04-11
RU2016133247A (ru) 2018-02-20
US20220098285A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
PH12016501763A1 (en) Multispecific antibodies
IL304772A (en) Antibodies, uses and methods
MX2017007941A (es) Anticuerpos antagonistas anti-axl.
TW201612191A (en) RSV-specific antibodies and functional parts thereof
MX2016016883A (es) Anticuerpo anti-axl.
MX2016016886A (es) Anticuerpos anti-axl.
EP3237439A4 (en) Compositions and methods for generating antigens, antibodies, and immunotherapeutic compositions and methods
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
IL268470A (en) A method for producing multispecific antibodies
EP3191128A4 (en) Uses of anti-her3 antibodies for treating cancer
FI3265123T3 (fi) Vasta-aineita, käyttöjä & menetelmiä
IL265016B (en) A method for purifying antibodies
EP3383497A4 (en) NEW ANTIBODIES FOR THE TREATMENT OF CANCERS
MX2019000246A (es) Formas en estado solido del dimesilato de palbociclib.
MX2020007742A (es) Procesos para preparar fluorocetolidos.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
EP3092002A4 (en) Method of purifying monoclonal antibodies
EP3108004A4 (en) Methods to produce single glycoform antibodies
HK1220727A1 (zh) 使用綿羊 細胞產生抗體的方法及其用途
EP3099652A4 (en) Synthesis of amonnium dinitramide, adn
EA201691203A1 (ru) Твёрдые формы тенофовира
EP3521307A4 (en) ANTIBODY ACQUISITION PROCESS
GB201413950D0 (en) Antibodies, uses & methods
GB201400597D0 (en) Antibodies, uses & methods

Legal Events

Date Code Title Description
FG Grant or registration